Vascular Nanotransfer Technologies Poised for Breakthrough
Interventional Applications with Its Next-Generation Drug-Coated-Balloon
(DCB) Platform Technology
Vascular Nanotransfer Technologies (“VNT”) (www.vnanotech.com [2]), an emerging medical technology company that has developed an innovative platform resulting in a proprietary Drug Coated Balloon (“DCB”), is featured in today’s issue of The Sentinel, published by OneMedPlace.
Click here for the complete story. [3]
About Vascular Nanotransfer Technologies (“VNT”)
Privately
held VNT, based in Auburndale, Mass., is developing Drug-Coated Balloons
(DCB) that are designed to be a more precise delivery vehicle and be the
standard treatment of choice for vascular atherosclerosis as well as
non-vascular applications.
CAUTION: VNT’s DCBs are not approved for sale.
Links:
[1] http://www.vnanotech.com
[2] http://cts.businesswire.com/ct/CT?id=smartlink&url=http://www.vnanotech.com&esheet=50552259&lan=en-US&anchor=www.vnanotech.com&index=1&md5=b13b2b1cad500dd3dd0f2b08e32c540d
[3] http://cts.businesswire.com/ct/CT?id=smartlink&url=http://www.onemedplace.com/blog/archives/12701&esheet=50552259&lan=en-US&anchor=Click here for the complete story.&index=2&md5=4eaaaa1b132654438cfbfffcc573f51a
[4] http://www.freshnews.com/node/715679